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1. GENERAL PART 
 
1.1. NEW PSYCHOACTIVE SUBSTANCES (NPS) 
The phenomenon of new psychoactive substances (NPS) showed continuously 
increasing impact worldwide and represent a challenge for public health.1 Such NPS 
are usually produced in bulk quantities by chemical and pharmaceutical companies 
e.g. in China or by clandestine laboratories either in Europe or elsewhere.1 They are 
most commonly distributed by specialized shops in the web under terms such as 
“research chemical”, “bath salts”, “plant food”, or “spice”. Despite their free 
availability, a misuse with or without overdosing might lead to severe and even fatal 
poisonings.1 After their appearance on the market and following misuse, they usually 
get controlled by international or national drug control laws with certain time offset. 
Then, the creation of new substances with similar chemical structures and effects 
appear, circumventing existing legislations making it a “cat and mouse game”.2 The 
corresponding NPS with lack of legal enforcement are therefore also branded as 
“legal highs”. To keep tracking the flood of compounds, several drug monitoring 
systems such as the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) or the United Nation Organization on Drugs and Crime (UNODC) register 
new upcoming NPS. This information is shared with the community by Early Warning 
Systems or can be found in annual drug reports amongst other statistical information. 
According to the European Drug Report 2017 by EMCDDA, the number of new 
detected substances increased over the last years.3 By the end of 2016, the 
appearance of more than 620 NPS could be monitored on the European drug 
market.1 The number of 66 new detected substances during 2016, however, was 
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lower than in previous years.1 This may lead to a positive trend, especially if it will 
sustain. However, the overall available NPS on the market still continue to grow 
despite slowing pace of new drug appearance.1 Reasons for that trend might be the 
introduction of blanket bans or generic and analogue-based legislation in different 
countries. In Germany, for example, such a new legislation was introduced in late 
2016, covering NPS that belong to groups of amphetamine-type stimulants including 
cathinones and synthetic cannabinoids.4 Although this law was a huge step forward, 
it did not cover all groups of NPS, yet. One of these uncovered groups was that of 
synthetic tryptamines, whose members are still among the most commonly reported 
NPS besides synthetic cathinones, synthetic cannabinoids, synthetic 
benzodiazepines, phenethylamines, piperazines, and synthetic opioids.1 This might 
lead to an increasing attention to this group in the following years.  
 
1.2. PHARMACOLOGY AND MISUSE OF TRYPTAMINE-DERIVED NPS 
The psychoactive effect of synthetic as well as biogenic tryptamines are mainly 
based on the interaction with the serotonergic system. They could activate serotonin 
(5-HT) receptors, could increase the 5-HT release, and/or act as 5-HT reuptake 
inhibitors at the corresponding transporters causing hallucinogenic and stimulating 
effects.5-8 Alexander and Ann Shulgin already described many synthetic tryptamines 
as potential entactogens in the book TiHKAL (Tryptamines I Have Known and Loved) 
in 1997.5,9 Here, detailed syntheses of 55 tryptamine-derived compounds and 
qualitative or quantitative comments are given to the effects, their duration, and the 
suggested dosage after self-experiments.9 Some of the described compounds 
appeared later on the drug market with reported misuse such as 5-methoxy-N,N-
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diisopropyltryptamine (5-MeO-DIPT), also known under names such as “Foxy 
methoxy”,10-13 or 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT).14 The latter 
belongs to the N,N-diallyltryptamine (DALT) derivatives, which represented an 
important group within the synthetic tryptamines.15 5-MeO-DALT and DALT itself 
were already described as hallucinogens in TiHKAL.9 Receptor binding profiles with 
structure-affinity relationships of these compounds as well as four further ring-
substituted derivatives were studied by Cozzi and Daley.15 They concluded that ring-
substituted derivatives, especially at 5-position, showed pharmacological potency15 
underlining again the probability that further DALT derivatives will once appear on the 
drug market as NPS. 
 
1.3. URINE SCREENING PROCEDURES 
For reliable drug testing, adherence monitoring, or detection of toxic compounds, 
several screening techniques are available.16 Common screening procedures using, 
for example, immunoassays allow fast detection of particular drugs or limited drug 
classes. However, results have to be confirmed due to the risk of false positives, at 
least in forensic cases. Furthermore, most of the NPS are not covered by such 
screenings with the consequence of overlooking. Therefore, screening procedures 
based on mass spectrometry (MS) techniques with low or high resolution (HR) are 
widely used, providing reliable and confirmed screening results with sufficient 
sensitivity.16-23 As further goal, a corresponding applied approach should allow 
comprehensive screening of a range of drugs and/or compounds. This could be 
achieved by analysis using full scan data, for example, with data dependent 
acquisition and library-based compound identification.16 Here, a higher number of 
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targets could be addressed and retrospective data processing is possible after 
updates of the corresponding reference library. As most drug screening procedures 
were performed in urine due to usually longer detection window and higher analyte 
concentrations, the metabolites of corresponding drugs have to be covered, 
especially when the metabolized form is excreted exclusively.24,25 For classic drugs, 
these metabolites are already investigated by the providing pharmaceutical 
companies. For NPS, however, the biotransformation is generally unknown. Thus, 
investigations on the NPS biotransformation by in vitro or in vivo studies are 
mandatory to identify their urinary excreted metabolites as screening targets. 
 
1.4. NOVEL SCREENING CONCEPTS 
1.4.1. DRIED MATRIX SPOTS 
Beyond screening approaches using conventional sampling, workup, or analysis, 
there was an increasing interest in alternatives in recent years.26-28 One of these 
alternatives were dried matrix spots (DMS). They represent a promising technique for 
microsampling as well as a strategy for sample collection and storage due to small 
sample volume requirements, high analyte stability, low transport and storage costs, 
and reduced infection risks.29 For sampling, only a few microliters of a fluid are 
spotted, soaked, and dried on a filter paper card whereby mainly blood or urine were 
used in context of drug screening. So far, only limited numbers of targets were 
covered in corresponding dried blood spot (DBS) or dried urine spot (DUS) screening 
approaches with focus on particular drugs or drug classes.30,31 However, a 
comprehensive DMS-based screening has not been described, yet.  
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1.4.2. PAPER SPRAY IONIZATION 
Most mass spectrometric analysis were performed after an appropriate preparation of 
the sample and sufficient separation of the analytes using gas chromatography (GC) 
or liquid chromatography (LC). These steps resulted in high sensitivity and 
robustness, but also prolonged turnaround time. One promising technique, which 
might allow the reduction of workload and analysis time, is paper spray ionization 
(PSI). For this ambient ionization technique, a small amount of a fluid is spotted, 
soaked, and dried on a triangular piece of paper in analogy to DUS sampling. For 
PSI, however, complex matrices such as blood or urine might be directly analyzed 
without time and work-consuming preparation. In the last years, the potential and 
advantages of PSI coupled to MS with low or HR were shown in various 
publications.32-37 In analogy to DUS screening approaches, however, published PSI 
approaches also covered only limited numbers of targets. Thus, a comprehensive 
PSI screening is still missing.  
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2. AIMS AND SCOPES 
 
The aim of this dissertation was the elucidation of the biotransformation as well as 
the toxicological NPS detectability in urine of the tryptamine-derived DALT and its 
ring-substituted derivatives 5-MeO-DALT, 5-fluoro-DALT, 7-methyl-DALT, and 5,6-
methylenedioxy-DALT. Their chemical structures are given in Figure 1. Furthermore, 
novel urine screening procedures for drug testing should be developed and validated 
by usage of DUS or PSI coupled to MS with low or HR. The approaches should then 
be compared to established procedures and techniques to show their possibilities 
and limitations. 
 
 
Figure 1. Chemical structure of the studied compounds N,N-diallyltryptamine (DALT),  
5-methoxy-DALT (5-MeO-DALT), 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT. 
 
The following steps had to be conducted: 
• Identification of the phase I and II metabolites of DALT, 5-MeO-DALT, 5-
fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in rat urine by 
LC-HR-tandem mass spectrometry (MS/MS) 
• Confirmation of the metabolic phase I steps after incubations with pooled 
human liver microsomes (pHLM) 
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• Investigation of the general involvement of human cytochrome P450 (CYP) 
isoenzymes in the main metabolic steps 
• Toxicological detectability in urine by standard urine screening approaches 
using GC-MS,38,39 LC-multi stage mass spectrometry (MSn),16,40 and LC-HR-
MS/MS23,41 approaches 
• Development of a DUS workup procedure for coupling to an established LC-
MSn approach16,40 for metabolite-based comprehensive screening 
• Validation of the new DUS approach according to international guidelines42,43 
using drugs of various drug classes 
• Comparison to screening after a conventional sample preparation16 by 
application to authentic human urine samples 
• Transfer of the DUS workup to a broad LC-HR-MS/MS drug screening23,41 
• Investigation of the screening power in comparison to established LC-MSn,16,40 
LC-HR-MS/MS,23,41 and GC-MS38,39 techniques by application to authentic 
human urine samples and rat urine samples after drug administration 
• Development of a suitable PSI setup and coupling to a HR-MS/MS system for 
developing a comprehensive urine screening for drug testing 
• Validation of the new PSI-HR-MS/MS approach according to international 
guidelines42,43 using drugs of various drug classes 
• Comparably testing of authentic human urine samples with the new PSI-HR-
MS approach or conventional LC-based approaches23,41 
 
PUBLICATIONS OF THE RESULTS 
 
9 
3. PUBLICATIONS OF THE RESULTS 
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4. DISCUSSION AND CONCLUSIONS 
 
4.1. METABOLISM AND DETECTABILITY STUDIES OF THE INVESTIGATED 
TRYPTAMINE-DERIVED NPS  
For the five studied tryptamines of the DALT group, an extensive metabolism was 
observed in rats. Considering the results obtained by incubations with pHLM, the 
same metabolites could be expected in humans. All in all, several aromatic and 
aliphatic hydroxylations, N-dealkylation, N-oxidation, and combinations thereof were 
proposed as the main metabolic pathways for all compounds as well as extensive 
glucuronidation or sulfation steps after phase I transformation. In addition, 
O-demethylation could be observed for 5-MeO-DALT, carboxylation after initial 
hydroxylation of the methyl group for 7-methyl-DALT, and O-demethylenation for 5,6-
methylenedioxy-DALT. For the formation of the phase I metabolites, several CYP 
isoenzymes were responsible. The following CYPs were generally involved: CYP2D6 
and CYP3A4 for all studied DALT derivatives; CYP1A2 and CYP2C19 for all 
derivatives except for DALT itself; CYP2C9 for 5-fluoro-DALT, 7-methyl-DALT and 
5,6-methylenedioxy-DALT; CYP2B6 for 5-fluoro-DALT and 7-methyl-DALT; and 
CYP3A5 only for 7-methyl-DALT. LC-MSn and LC-HR-MS/MS were suitable for 
monitoring consumption of all compounds after rat doses of 1 mg/kg body weight, 
respectively, which corresponded to a human dose of approximately 10 mg. The 
most abundant LC screening targets were as follows: for DALT a hydroxy-aryl 
metabolite and its glucuronide; for 5-MeO-DALT the N,O-bis-dealkyl metabolite and 
its glucuronide, for 5-fluoro-DALT one of two hydroxy-aryl metabolites and both 
corresponding glucuronides; for 7-methyl-DALT one N-deallyl-hydroxy-aryl, the 
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carboxy, and one dihydroxy-aryl metabolite; and for 5,6-methylenedioxy-DALT the 
demethylenyl metabolite, as well as its oxo metabolite and its glucuronide. In 
addition, a consumption of DALT should also be detectable by GC-MS via its main 
phase I metabolites. For the compounds 5-fluoro-DALT, 7-methyl-DALT, and 5,6-
methylenedioxy-DALT, no data were available for drug dose or potency and thus the 
expected human users’ dose could also be lower than 10 mg. Therefore, a 10-fold 
lower rat dose of 0.1 mg/kg body weight was additionally studied for these 
compounds to verify reliable detection. 5-fluro-DALT and 7-methyl-DALT could be 
detected by the LC-HR-MS/MS screening, 5-fluro-DALT in addition by the LC-MSn 
approach. However, a reliable monitoring of 5,6-methylenedioxy-DALT could not be 
achieved after administration of such low doses. Here, an alternative sample 
preparation should be performed.  
 
4.2. DRIED URINE SPOTS AS ALTERNATIVE SAMPLING FOR LC-MS URINE 
SCREENING APPROACHES 
The developed workup using DUS consisted of spotting on filter paper cards and 
enzymatic on-spot conjugate cleavage followed by liquid extraction (DUSglucE) and 
was coupled to LC-MSn or LC-HR-MS/MS. For successful validation42,43 of the 
workup, model compounds of several drug classes (antidepressants, 
benzodiazepines, cardiovascular drugs, neuroleptics, opioids, stimulants, etc.) were 
selected, covering a broad range of (physico-)chemical properties and 
chromatographic behaviors. By testing of the parameters recommended for 
qualitative approaches by LC-MSn, the novel DUS workup showed results 
comparable to established urine precipitation (UP) with acetonitrile.16 However, an 
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additional conjugate cleavage was necessary due to the basified extraction with low 
expected recoveries for glucuronides and sulfates. Hence, an on-spot deconjugation 
was included and tested with seven common phase II metabolites. The hydrolysis 
efficiencies were sufficient for most compounds and comparable to conventional 
cleavage procedures. It allowed reliable detection especially for drugs with high 
urinary glucuronide excretion. For applicability testing, 103 authentic human urine 
samples were analyzed as well as six rat urine samples after 0.1 mg/kg body weight 
substance administrations. The latter were tested to assess the sensitivity after 
DUSglucE for such low-dosed compounds with extensive metabolism and thus high 
target spreads. 5-Fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT were 
chosen for testing after rat administration as well as 2-(4-iodo-2,5-dimethoxyphenyl)-
N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe), 25-bromo-NBOMe (25B-
NBOMe), and 25-chloro-NBOMe (25C-NBOMe). For these compounds, extensive 
biotransformation and/or consumption in very low doses were described.44,45,49,50 The 
DUSglucE was compared to an established workup by UP, which was performed 
without and with conjugate cleavage to assess its actual impact on the detectability. 
Furthermore, a comprehensive screening procedure by GC-MS38 was additionally 
tested as this technique was the gold standard for drug screening for a long time.18 
The screening results were obtained after splitting the urine samples into four parts 
and worked up by (i) UP,16,23 (ii) UP with conjugate cleavage (UglucP), or (iii) 
DUSglucE for LC-MSn and LC-HR-MS/MS analysis. For GC-MS analysis, (iv) acid 
hydrolysis was performed, followed by liquid-liquid extraction, and acetylation 
(UHyAc).38 For comparison of the different approaches and workups, the 770 
detected drug intakes were set to 100%. In the LC-MSn approach, the detected drug 
intakes ranged from 41-49%. In comparison, the LC-HR-MS/MS approach was able 
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to detect at least over one‐third more drug intakes. In detail, 77% of the drug intakes 
were detected after DUSglucE, which was comparable to 80% after UP. After 
UglucP, overall impact of the deconjugation was shown to be +9%. The differences 
to DUSglucE should be caused mainly by the smaller urine volumes used. Moreover, 
the value of drug intakes identified by the GC-MS approach after UHyAc was 56%, 
lying between both LC-based screening approaches. Concerning the rat urine 
samples, an intake could not be reliably monitored in the LC-MSn approach after the 
tested workups. Only the LC-HR-MS/MS approach was able to detect the 
compounds after UP and UglucP as well as after DUSglucE, what underlined the 
high sensitivity of the LC-HR-MS/MS system. In conclusion, DUS might be an 
alternative sampling technique for comprehensive metabolite-based drug testing or 
adherence monitoring showing best screening results after coupling to LC-HR-
MS/MS. 
 
4.3. NEW PAPER SPRAY IONIZATION-HR-MS/MS APPROACH AS 
PROMISING ALTERNATIVE FOR COMPREHENSIVE URINE DRUG 
TESTING 
The new PSI-HR-MS/MS approach was developed for reliable screening of a broad 
range of drugs of different drug classes and successfully validated.42,43 For validation, 
again exemplary compounds were used which covered a broad range of chemical 
and physicochemical properties in analogy to the validation of the DUSglucE. The 
procedure showed high matrix effects for most drugs. Nevertheless, the limits of 
identification were acceptable for a broad urine screening and comparable with 
procedures using LC.23 In addition, the international cut-off recommendations for the 
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tested drugs of abuse51 were fulfilled. However, the detection of drugs in low 
concentrations and the risks of analyte carry-over marked limitations of the approach. 
Furthermore, it should be aware of false positive/negative results caused by mixed 
spectra due to the lack of analyte separation. For applicability testing, the identical 
authentic human urine samples were used as described for the DUSglucE study. 
This allowed a direct comparison of the results by the different approaches. In the 
new PSI-HR-MS/MS approach, 73% of all drug intakes were detectable. Among 
them, seven drug intakes could be detected only using the new approach, raising the 
total drug intakes to 777. Both LC-based approaches could detect more drugs with 
values of 88% after UglucP or 76% after DUSglucE. However, these discrepancies 
were mostly due to low urine concentrations of corresponding targets. In conclusion, 
these results showed that the PSI technology could become a promising alternative 
to conventional procedures. Nevertheless, limitations such as detection of drugs in 
low concentrations and risk of false positive or negative results caused by mixed 
spectra should be addressed in prospective studies. 
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5. SUMMARY 
 
Biotransformation and detectability in urine were studied for the new psychoactive 
substances N,N-diallyltryptamine (DALT) and its derivatives 5-methoxy-DALT, 5-
fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT. They all showed 
extensive metabolism catalyzed by several CYP isoenzymes. In addition, novel 
concepts for urine drug screening were investigated. For dried urine spot (DUS)-
based screening, sufficient workup with on-spot conjugate cleavage was developed 
for a broad range of different drugs showing sufficient urine screening results of 
authentic human samples after LC-MSn or LC-high resolution (HR)-MS/MS analysis, 
comparable with those obtained after established urine precipitation workup with or 
without conjugate cleavage. For paper spray ionization (PSI)-based screening, the 
PSI setup was modified and coupled to HR-MS/MS. Again, confirmation of drug 
intakes was comparable to LC-based screening approaches. However, the detection 
of drugs in low concentrations and the risk of false positive or negative results caused 
by mixed spectra set some limitations to this setup. In conclusion, the sampling by 
DUS and the direct urine analysis by PSI was suitable for comprehensive metabolite-
based drug testing and adherence monitoring of different drugs and drug classes by 
coupling to LC-MSn or LC-HR-MS/MS. They may become alternative strategies with 
the potential of reducing costs for sample collection and storage or workload. 
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7. ABBREVIATIONS 
 
25B-NBOMe 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]-
ethanamine 
25C-NBOMe 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]-
ethanamine 
25I-NBOMe 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]-
ethanamine 
5-HT serotonin 
5-MeO-DALT 5-methoxy-N,N-diallyltryptamine 
5-MeO-DIPT 5-methoxy-N,N-diisopropyltryptamine 
CYP human cytochrome P450 
DALT N,N-diallyltryptamine 
DBS dried blood spot 
DMS dried matrix spots 
DUS dried urine spot 
DUSglucE DUS spotting, enzymatic conjugate cleavage, and liquid extraction 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
GC gas chromatography 
HR high resolution 
LC liquid chromatography 
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MS mass spectrometry 
MS/MS tandem mass spectrometry 
MSn multi stage mass spectrometry 
NPS new psychoactive substances 
pHLM pooled human liver microsomes 
PSI paper spray ionization 
UglucP urine precipitation with conjugate cleavage 
UHyAc acid hydrolysis, liquid-liquid extraction, and acetylation 
UNODC United Nation Organization on Drugs and Crime 
UP urine precipitation 
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8. ZUSAMMENFASSUNG 
 
Für die neuen psychoaktiven Stoffe N,N-Diallyltryptamin (DALT), 5-Methoxy-DALT, 
5-Fluor-DALT, 7-Methyl-DALT, und 5,6-Methylendioxy-DALT wurden Metabolismus 
und Detektierbarkeit im Urin untersucht. Alle Substanzen zeigten ausgeprägte 
Metabolisierung, katalysiert durch mehrere CYP Enzyme. Danach wurden neue 
Screeningkonzepte erforscht. Für das Konzept mit dried urine spots (DUS) wurde 
eine umfassende Aufarbeitung mit Konjugatspaltung entwickelt. Gekoppelt mit LC-
MSn oder LC-high resolution (HR)-MS/MS waren die Screeningergebnisse von 
authentischen Urinproben vergleichbar mit denen nach etablierter Urinpräzipitation 
mit oder ohne Konjugatspaltung. Das paper spray ionization (PSI)-basierte 
Screeningverfahren wurde mit HR-MS/MS gekoppelt und lieferte vergleichbare 
Ergebnisse wie LC-basierte Screeningverfahren. Allerdings stellten sich die 
Substanzdetektion in niedrigen Konzentrationen sowie das Risiko von falsch-
positiven oder -negativen Resultaten durch überlagerte Spektren als Limitierungen 
dieses Verfahrens heraus. Zusammenfassend erwies sich die Probennahme per 
DUS und die direkte Urinanalyse mittels PSI gekoppelt mit LC-MSn und/oder LC-HR-
MS/MS als geeignet für umfassendes und Metaboliten-basiertes Drogenscreening 
oder Adhärenzkontrolle. Dies ermöglichte es verschiedenste Arzneistoff- und 
Drogenklassen zu erfassen, weshalb diese Techniken Alternativen werden können 
um die Kosten für Probennahme und -lagerung zu reduzieren, sowie den 
Arbeitsaufwand für die Probenaufarbeitung. 
